Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Gelesis Holdings, Inc. (GLS)

0.18   0.01 (5.88%) 03-27 16:00
Open: 0.1785 Pre. Close: 0.17
High: 0.18 Low: 0.1502
Volume: 723,808 Market Cap: 13(M)

Technical analysis

as of: 2023-03-27 4:19:42 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.28     One year: 0.38
Support: Support1: 0.1    Support2: 0.09
Resistance: Resistance1: 0.24    Resistance2: 0.32
Pivot: 0.19
Moving Average: MA(5): 0.16     MA(20): 0.21
MA(100): 0.3     MA(250): 1.58
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 34.6     %D(3): 29.6
RSI: RSI(14): 42.6
52-week: High: 5.94  Low: 0.1
Average Vol(K): 3-Month: 376 (K)  10-Days: 1,219 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GLS ] has closed above bottom band by 38.8%. Bollinger Bands are 25.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.17 - 0.17 0.17 - 0.17
Low: 0.14 - 0.14 0.14 - 0.14
Close: 0.17 - 0.17 0.17 - 0.17

Company Description

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Headline News

Fri, 24 Mar 2023
Markets Today: Stock Indexes Slump on Banking Sector Woes - Barchart

Fri, 24 Mar 2023
North American Morning Briefing : Stock Futures -2- - Marketscreener.com

Wed, 22 Mar 2023
Why GameStop Shares Are Trading Higher By Around 44%; Here ... - Investing.com UK

Tue, 21 Mar 2023
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are ... - Investing.com UK

Tue, 21 Mar 2023
Where Will Gelesis Holdings Inc (GLS) Stock Go Next After It Has Fallen 31.82% in a Week? - InvestorsObserver

Tue, 21 Mar 2023
Real-Time Update: Gelesis Holdings Inc. (GLS) Stock Navigates the ... - The News Heater

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 73 (M)
Shares Float 20 (M)
% Held by Insiders 52.2 (%)
% Held by Institutions 32.8 (%)
Shares Short 513 (K)
Shares Short P.Month 712 (K)

Stock Financials

EPS -1.34
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.06
Profit Margin (%) -198.5
Operating Margin (%) -443.7
Return on Assets (ttm) -51.8
Return on Equity (ttm) -552.4
Qtrly Rev. Growth 120.6
Gross Profit (p.s.) 0.01
Sales Per Share 0.35
EBITDA (p.s.) -1.51
Qtrly Earnings Growth 0
Operating Cash Flow -90 (M)
Levered Free Cash Flow -82 (M)

Stock Valuations

PE Ratio -0.14
PEG Ratio 0
Price to Book value -3.59
Price to Sales 0.5
Price to Cash Flow -0.15

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.